Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation to establish False Claims Act (FCA) liability based on violations of the...more
2/21/2025
/ Anti-Kickback Statute ,
Compliance ,
Department of Health and Human Services (HHS) ,
False Claims Act (FCA) ,
Healthcare Fraud ,
Life Sciences ,
Medicare ,
Pharmaceutical Industry ,
Risk Management ,
Safe Harbors ,
Whistleblowers
Over the past year, the Biden administration has expressed serious doubts about the developing role of private equity investment in the long term care industry. In a Fact Sheet released in late February 2022, the White House...more